Zoetis(NYSE) ZTS

Market Cap$30.92B

Since IPO (2013)+163%

5 Year-60%

1 Year-48%

1 Month-0%

$74.71

+2.82%

+2.05Today

After hours$74.86+$0.15 (+0.20%)

Zoetis last closing stock price
Metric	Price	Date
Last close	USD 74.83	2026-08-10

Zoetis stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.94%	USD 77.10	2026-08-03
1 month	-0.28%	USD 75.04	2026-07-10
3 month	-2.06%	USD 76.41	2026-05-12
Year to date	-39.59%	USD 123.88	2025-12-31
1 year	-48.24%	USD 144.57	2025-08-08
3 year	-59.15%	USD 183.16	2023-08-11
5 year	-59.9%	USD 186.62	2021-08-11
Since inception	+163.22%	USD 27.60	2013-02-01

Zoetis Financials at a Glance

Market Cap

$30.92B

Revenue (TTM)

$9.52B

Net Income (TTM)

$2.62B

EPS (TTM)

$6.08

P/E Ratio

12.31

Dividend

$2.09

Beta (Volatility)

0.81 (Low)

Dividend

$2.09

Beta (Volatility)

0.81 (Low)

Price

$74.71

Volume

9,610,018

Open

$72.40

Price

$74.71

Volume

9,610,018

Open

$72.40

Previous Close

$74.83

Daily Range

$71.45 - $74.98

52-Week Range

$71.45 - $160.48

Estimated Earnings Date

Nov 3, 2026

Dividend

$2.09

Beta (Volatility)

0.81 (Low)

Price

$74.71

Volume

9,610,018

Open

$72.40

Previous Close

$74.83

Daily Range

$71.45 - $74.98

52-Week Range

$71.45 - $160.48

Estimated Earnings Date

Nov 3, 2026

ZTS News

This Animal Health Stock Is Trading at Its Lowest P/E Ratio Ever

Justin PopeApr 25, 2026

2 Healthcare Stocks to Buy and 1 to Approach With Caution

Prosper Junior BakinyApr 15, 2026

Veterinarian cat sick pet health-1200x800-5b2df79

Should You Buy Zoetis Before Feb. 12?

Thomas NielFeb 9, 2026

2 Healthcare Stocks Poised for a Comeback in 2026

Prosper Junior BakinyJan 22, 2026

This Could Be One of the Best Healthcare Stock Buying Opportunities I've Seen in Years

Josh Kohn-LindquistJan 22, 2026

Page 1

ZTS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zoetis

Zoetis makes medicines and vaccines to keep pets and farm animals healthy. The company helps veterinarians and farmers find and treat animal diseases. Its products help animals live longer and ensure a safe food supply.

What Zoetis Sells

Companion Animal Products: Medicines, vaccines, and diagnostic tests for dogs, cats, and horses; accounts for 70% of revenue.
Livestock Products: Health solutions for cattle, swine, poultry, fish, and sheep; accounts for 29% of revenue.
Parasiticides: Products that prevent or kill parasites like fleas, ticks, and worms.
Dermatology: Specialized treatments for skin allergies and itching in dogs.
Animal Health Diagnostics: Tools and kits used for testing blood and urine samples in clinics.

Recent Moves and Milestones

Acquired Veterinary Pathology Group in 2025 to expand diagnostic lab services in the U.K. and Ireland.
Divested the medicated feed additive product portfolio and related assets on October 31, 2024.
Purchased a manufacturing site near Atlanta, Georgia in 2023 to increase future production capacity.
Acquired PetMedix Ltd and adivo GmbH in 2023 to develop new antibody therapies for pets.
Expanded the Abaxis portfolio in 2023 by adding artificial intelligence features to the Vetscan Imagyst platform.

A Global Health Network

The company operates 21 manufacturing sites and sells products in more than 100 countries. It uses a direct sales force of 3,900 employees to maintain relationships with veterinarians and livestock producers.

By the Numbers

Revenue reached $2.4 billion in Q4 2025, up 3% from Q4 2024.
Operating income rose to $826 million in Q4 2025, an 8% increase year-over-year.
Net income grew to $603 million in Q4 2025, up 3.8% from the previous year.
Free cash flow was $732 million in Q4 2025, up 6.2% from Q4 2024.
Research and development spending totaled $698 million for the full year 2025.

Bottom Line

Zoetis has transitioned from a division of Pfizer into an independent leader in animal healthcare. The company continues to evolve by combining traditional medicines with digital diagnostics and biotechnology.

AI Generated • Apr 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,500

CEO

Kristin C. Peck, MBA

Website

www.zoetis.com

Headquarters

Parsippany, NJ 07054, US

ZTS Financials

Key Financial Metrics (TTM)

Gross Margin

70.87%

Operating Margin

37.00%

Net Income Margin

27.49%

Return on Equity

69.25%

Return on Capital

28.05%

Return on Assets

17.35%

Earnings Yield

8.12%

Dividend Yield

2.79%

Payout Ratio

42.55%

Stock Overview

Market Cap

$30.92B

Shares Outstanding

413.22M

Volume

9.61M

Avg. Volume

7.52M

Financials (TTM)

Gross Profit

$6.75B

Operating Income

$3.52B

EBITDA

$3.87B

Operating Cash Flow

$3.29B

Capital Expenditure

-$631.00M

Free Cash Flow

$2.66B

Cash & ST Invst.

$1.68B

Total Debt

$190.00M

Zoetis Performance Analysis

Zoetis annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 8,080,000,000	3.9%
2023	2023-12-31	USD 8,544,000,000	5.7%
2024	2024-12-31	USD 9,256,000,000	8.3%
2025	2025-12-31	USD 9,467,000,000	2.3%

Zoetis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-2.4%
Q4	2025-12-31	-0.5%
Q1	2026-03-31	-5.2%
Q2	2026-06-30	9.1%

Zoetis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD 4.49	5.2%
2023	2023-12-31	USD 5.07	12.8%
2024	2024-12-31	USD 5.47	7.8%
2025	2025-12-31	USD 6.02	10.2%

Zoetis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	1.2%
Q4	2025-12-31	-16.0%
Q1	2026-03-31	3.6%
Q2	2026-06-30	16.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$2.47B

+0.3%

Gross Profit

$1.80B

+1.0%

Gross Margin

72.73%

N/A

Market Cap

$30.92B

N/A

Market Cap/Employee

$2.13M

N/A

Employees

14,500

N/A

Net Income

$691.00M

-3.8%

EBITDA

$927.00M

-14.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$1.68B

+16.8%

Total Debt

$190.00M

-97.2%

Accounts Receivable

$1.57B

+2.0%

Inventory

$2.57B

+5.5%

Long Term Debt

$380.00M

-93.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

17.35%

N/A

Return on Invested Capital

27.05%

N/A

Free Cash Flow

$829.00M

+169.2%

Operating Cash Flow

$1.06B

+117.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HLNHaleon plc

HLNHaleon plc$9.93-1.00%

IDXXIDEXX Laboratories, Inc.

IDXXIDEXX Laboratories, Inc.$595.76+1.55%

BDXBecton, Dickinson and Company

BDXBecton, Dickinson and Company$179.63+1.57%

ELANElanco Animal Health Incorporated

ELANElanco Animal Health Incorporated$22.29+0.77%

ARGXargenx SE

ARGXargenx SE$866.11+0.12%

TAKTakeda Pharmaceutical Company Limited

TAKTakeda Pharmaceutical Company Limited$17.55+0.57%

CORCencora, Inc.

CORCencora, Inc.$325.00+1.42%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$138.74+0.04%

ACHRArcher Aviation

ACHRArcher Aviation$6.26+0.12%

NVDANvidia

NVDANvidia$217.55-0.03%

INTCIntel

INTCIntel$97.52-0.04%

ONDSOndas

ONDSOndas$9.31+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.21+0.01%

RIGTransocean

RIGTransocean$5.72+0.09%

Questions About ZTS

What is the current price of Zoetis?

Zoetis is trading at $74.83 per share.

What is the 52-week range for Zoetis?

Over the past 52 weeks, Zoetis has traded between $71.45 and $160.48.

How much debt does Zoetis have?

As of the most recent reporting period, Zoetis reported total debt of $9.24B.

How much cash does Zoetis have on hand?

Zoetis reported $1.48B in cash and cash equivalents in its most recent financial results.

What is Zoetis’s dividend yield?

Zoetis currently has a dividend yield of 2.79%.

Zoetis(NYSE) ZTS

Zoetis Financials at a Glance

ZTS News

Best Food ETFs to Buy in 2026

Best Pet Food Stocks to Buy in 2026: Are They Right for Your Portfolio?

Why Zoetis Shares Plummeted Today

This Animal Health Stock Is Trading at Its Lowest P/E Ratio Ever

2 Healthcare Stocks to Buy and 1 to Approach With Caution

Should You Buy Zoetis Before Feb. 12?

2 Healthcare Stocks Poised for a Comeback in 2026

This Could Be One of the Best Healthcare Stock Buying Opportunities I've Seen in Years

ZTS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Zoetis

What Zoetis Sells

Recent Moves and Milestones

A Global Health Network

By the Numbers

Bottom Line

ZTS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Zoetis Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ZTS

What is the current price of Zoetis?

What is the 52-week range for Zoetis?

How much debt does Zoetis have?

How much cash does Zoetis have on hand?

What is Zoetis’s dividend yield?

Premium Investing Services